Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. NOXXON Pharma N.V.
  6. News
  7. Summary
    ALNOX   NL0012044762

NOXXON PHARMA N.V.

(ALNOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NOXXON Pharma N : to Expand Ongoing Early-Stage Brain Cancer Study; Shares Down 5%

08/05/2021 | 04:22am EDT


ę MT Newswires 2021
All news about NOXXON PHARMA N.V.
10/06NOXXON PHARMA N : announces upcoming oral presentation at the Society for Neuro-Oncology A..
PU
09/29GLOBAL MARKETS LIVE : Sanofi, ASML, Apple, United Airlines, Netflix...
09/22NOXXON PHARMA N : Enrolls Last Patient For Phase 1/2 Trial Of Brian Cancer Treatment
MT
09/22NOXXON Pharma N.V Enrolls Last Brain Cancer Patient in Dose Escalation Portion of GLORI..
CI
09/22NOXXON PHARMA N : enrolls last brain cancer patient in dose escalation portion of GLORIA s..
PU
08/25NOXXON PHARMA N : to attend the German Fall conference on September 6 & 7, 2021
PU
08/05GLOBAL MARKETS LIVE : Robinhood, Bayer, MetLife, Uber, WPP...
08/05NOXXON PHARMA N : to Expand Ongoing Early-Stage Brain Cancer Study; Shares Down 5%
MT
08/05NOXXON Provides Update on NOX-A12 Clinical Programs
CI
07/28NOXXON PHARMA N : Half-yearly report on the liquidity contract with Invest Securities
PU
More news
Financials
Sales 2020 0,04 M 0,04 M 0,04 M
Net income 2020 -10,4 M -12,1 M -12,1 M
Net cash 2020 10,2 M 11,8 M 11,8 M
P/E ratio 2020 -1,75x
Yield 2020 -
Capitalization 21,1 M 24,5 M 24,5 M
EV / Sales 2019 41,1x
EV / Sales 2020 405x
Nbr of Employees 12
Free-Float 19,5%
Chart NOXXON PHARMA N.V.
Duration : Period :
NOXXON Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOXXON PHARMA N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Aram Andrew Mangasarian Chief Executive Officer & Director
Maurizio PetitBon Chairman-Supervisory Board
Bertram K÷hler Member-Supervisory Board
Cornelis Alexander Izeboud Member-Supervisory Board
Joseph Donald DeBethizy Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
NOXXON PHARMA N.V.-46.73%24
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414